- 501. Parasympathetic Ganglion
- [Ganglia of the parasympathetic nervous system, including the ciliary, pterygopalatine, submandibular, and otic ganglia in the cranial region and intrinsic (terminal) ganglia associated with target organs in the thorax and abdomen. ( MSH )] (UMLS (NCI) C0017069) =Body Part, Organ, or Organ Component ;
| - 551. ParenteralRoute
- [Parenteral ( HL7V3.0 )] (UMLS (HL7) C1700180) =Functional Concept =RouteBySite;
=Injection, parenteral |
- 502. parasympathetic nervous system
- [craniosacral division of the autonomic nervous system; generally acts to conserve resources and restore homeostasis, often with effects reciprocal to the sympathetic nervous system; cell bodies of the parasympathetic preganglionic fibers are in brain stem nuclei and in the sacral spinal cord; they synapse in cranial autonomic ganglia or in terminal ganglia near target organs. ( CSP )] (UMLS (CSP) C0030510) =Body System =ANS;
=cranial nerve X;
ciliary ganglion | - 552. parenting
- [Performing the role of a parent by care-giving, nurturance, and protection of the child by a natural or substitute parent. The parent supports the child by exercising authority and through consistent, empathic, appropriate behavior in response to the child's needs. PARENTING differs from CHILD REARING in that in child rearing the emphasis is on the act of training or bringing up the children and the interaction between the parent and child, while parenting emphasizes the responsibility and qualities of exemplary behavior of the parent. ( MSH )] (UMLS (CSP) C0085092) =Social Behavior ;
|
- 503. parasympathomimetic agent
- [Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. ( MSH )] (UMLS (CSP) C0030512) =Pharmacologic Substance
| - 553. Pareptide
- (UMLS (NCI) C0070110) =Amino Acid, Peptide, or Protein ;
|
- 504. paraterminal body
- [ ] (UMLS (CSP) C0598032) =Body Part, Organ, or Organ Component ;
| - 554. PARESIS OF ACCOMMODATION
- [ ] (UMLS (ICD9CM) C0235238) =Disease or Syndrome
|
- 505. Paratesticular Lipoma
- [A rare benign adipose tissue neoplasm of the paratesticular tissues. It is incidentally discovered and presents as a non-tender scrotal mass. It affects patients over a wide age range. ( NCI )] (UMLS (NCI) C1335348) =Neoplastic Process
| - 555. Paresthesia
- [Abnormal touch sensations, such as burning or prickling, that occur without an outside stimulus. ( NCI )] (UMLS (NCI) C0030554) =Sign or Symptom ;
=Somatosensory Disorders;
|
- 506. parathion
- [agricultural insecticide highly toxic to humans and animals. ( CSP )] (UMLS (CSP) C0030514) =Organophosphorus Compound; Hazardous or Poisonous Substance ;
=organophosphorus insecticide;
| - 556. Pargeverine
- (UMLS (NCI) C0771729) =Organic Chemical; Pharmacologic Substance
|
- 507. parathormone
- [ ] (UMLS (CSP) C0202159) =Laboratory Procedure
| - 557. Pargolol
- (UMLS (NCI) C0070112) =Organic Chemical; Pharmacologic Substance
|
- 508. Parathormone
- [Encoded by human PTH Gene (Parathyroid Hormone Family), secreted (parathyroid cells) 115-aa 13-kDa (precursor) Parathyroid Hormone elevates blood Ca2+ levels by dissolving the salts in bone and preventing renal excretion. PTH defects cause familial isolated hypoparathyroidism. (NCI) ( NCI )] (UMLS (NCI) C0020063) =Amino Acid, Peptide, or Protein; Hormone
| - 558. PARGYLINE
- [A monoamine oxidase inhibitor with antihypertensive properties. ( MSH )] (UMLS (NCI) C0030557) =Organic Chemical; Pharmacologic Substance =benzylamine;
[CV490] ANTIHYPERTENSIVES, OTHER;
TO BE DELETED INGREDIENT PREPARATIONS;
=PARGYLINE HYDROCHLORIDE |
- 509. Parathyroid Gland Abscess
- (UMLS (NCI) C1112498) =Pathologic Function
| - 559. Parietal
- [Of, or relating to, or associated with the parietal bones. ( NCI )] (UMLS (NCI) C0442030) =Spatial Concept =Body Part;
|
- 510. Parathyroid Gland Capsule
- (UMLS (NCI) C0927176) =Body Part, Organ, or Organ Component
| - 560. Parietal Bone
- (UMLS (NCI) C0030558) =Body Part, Organ, or Organ Component ;
|
- 511. Parathyroid Gland Chief Cell
- [The primary cell of the parathyroid gland. Its contains secretory granules, large Golgi complexes, and moderate numbers of mitochondria. It produces parathyroid hormone. The cells occur in sheets interspersed with areas of fatty tissue. Occasionally the cells are arranged in follicles. ( NCI )] (UMLS (NCI) C0229586) =Cell
| - 561. Parietal Cell
- [Cells of the gastric glands which secrete hydrochloric acid and intrinsic factor. (MeSH) ( NCI )] (UMLS (NCI) C0030559) =Cell ;
|
- 512. Parathyroid Gland Oncocytic Adenoma
- [A parathyroid gland adenoma composed predominantly or entirely of neoplastic cells with abundant granular eosinophilic cytoplasm. (NCI05) ( NCI )] (UMLS (NCI) C1335351) Parathyroid Oncocytic Adenoma =Neoplastic Process
| - 562. Parietal Cell Adenocarcinoma
- [An adenocarcinoma of the stomach arising from the parietal cells. It is characterized by the presence of malignant cells with eosinophilic, finely granular cytoplasm. ( NCI )] (UMLS (NCI) C1266026) =Neoplastic Process
|
- 513. Parathyroid Gland Oxyphil Cell
- [A cell of the parathyroid gland that has condensed chromatin in a small round nucleus. Its cytoplasm is composed of tightly packed mitochondria and glycogen granules, with rare secretory granules, stains pink, and the margin is usually observed. ( NCI )] (UMLS (NCI) C0229589) =Cell
| - 563. Parietal Layer of Bowman's Capsule
- (UMLS (NCI) C0227645) =Body Part, Organ, or Organ Component
|
- 514. Parathyroid Gland Water-Clear Cell Adenoma
- [A rare parathyroid gland adenoma composed of neoplastic cells with abundant cytoplasm. The cytoplasm of the neoplastic cells is usually not entirely clear, and is often variably vacuolated, foamy, and granular. ( NCI )] (UMLS (NCI) C0334321) =Neoplastic Process
| - 564. parietal lobe/cortex
- [upper central part of the cerebral hemisphere. ( CSP )] (UMLS (CSP) C0228210) =Body Part, Organ, or Organ Component =cerebral cortex;
|
- 515. parathyroid hormone
- [polypeptide hormone secreted by the parathyroid glands which maintains intracellular calcium levels in the body; parathyroid hormone increases intracellular calcium by promoting the release of calcium from bone, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. ( CSP )] (UMLS (CSP) C0030520) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Hormone =Peptide Hormone;
| - 565. Parietal Pleura
- [The outermost of the two pleural membranes. It consists of a thin basal layer of fibrous tissue upon which sits a continuous layer of mesothelial cells. The cells function to secrete the lubricant lining the pleural cavity. ( NCI )] (UMLS (NCI) C0225777) =Body Part, Organ, or Organ Component
|
- 516. Parathyroid Hormone Gene
- [This gene plays a role in blood calcium regulation. Defects in the gene are associated with familial isolated hypoparathyroidism. ( NCI )] (UMLS (NCI) C1419072) PTH;
PTH Gene =Gene or Genome | - 566. Parinaud Syndrome
- (UMLS (NCI) C0152222) =Disease or Syndrome ;
|
- 517. Parathyroid Hormone Like Tumor Factor
- [calcium-regulating hormone with endocrine, paracrine, and autocrine actions in bone; can cause hypercalcemia. ( CSP )] (UMLS (NCI) C0070099) =Amino Acid, Peptide, or Protein; Hormone =Peptide Hormone;
| - 567. PARINFLUENZA VIRAL PNEUM
- [ ] (UMLS (ICD9CM) C0276333) =Disease or Syndrome
|
- 518. Parathyroid Hormone-Like Hormone Gene
- [This gene is involved in the differentiation and proliferation of chondrocytes during endochondrial ossification. It also plays a role in lactation. ( NCI )] (UMLS (NCI) C1335272) PTHLH;
PTHLH Gene =Gene or Genome | - 568. Park
- (UMLS (NCI) C0562547) =Manufactured Object ;
|
- 519. PARATHYROID REIMPLANT
- [ ] (UMLS (ICD9CM) C0176108) =Therapeutic or Preventive Procedure
| - 569. Parkedale Pharmaceuticals
- (UMLS (HL7) C1546889) =Health Care Related Organization =Manufacturers of Vaccines (code=MVX);
|
- 520. PARATHYROID SCAN
- (UMLS (ICD9CM) C0203792) =Diagnostic Procedure
| - 570. Parkedale Pharmaceuticals (formerly Parke-Davis)
- [Parkedale Pharmaceuticals (formerly Parke-Davis) ( HL7V3.0 )] (UMLS (HL7) C1552899) =Health Care Related Organization ;
=VaccineManufacturer;
|
- 521. parathyroid transplantation
- [ ] (UMLS (CSP) C0193755) =Therapeutic or Preventive Procedure
| - 571. parkin gene
- [ ] (UMLS (CSP) C1537041) =Gene or Genome ;
|
- 522. parathyroidectomy
- [excision of the parathyroid gland or glands. ( CSP )] (UMLS (CSP) C0079989) =Therapeutic or Preventive Procedure ;
=endocrine surgery;
| - 572. parkin gene/protein
- [putative ubiquitin ligase component that causes an autosomal recessive type of Parkinson's disease. ( CSP )] (UMLS (CSP) C1537074) =Gene or Genome ;
=enzyme;
gene;
ubiquitin;
|
- 523. Paratracheal
- [Regions near to the trachea. ( NCI )] (UMLS (NCI) C0442143) =Spatial Concept ;
=Body Part;
| - 573. parkin protein
- [ ] (UMLS (CSP) C0673396) =Amino Acid, Peptide, or Protein; Biologically Active Substance
|
- 524. Paratyphoid Fever
- [A prolonged febrile illness commonly caused by several Paratyphi serotypes of SALMONELLA ENTERICA. It is similar to TYPHOID FEVER but less severe. ( MSH )] (UMLS (NCI) C0030528) =Disease or Syndrome =Salmonella infection;
| - 574. Parkinsonism
- [A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.(MSH)] (UMLS (ICPC) C0242422) (Parkinsonism; PARKINSON/PARALISI IRABIATZAILEA; Parkinsonisme/paralysis agitans; Parkinsonisme, ziekte v Parkinson; PARKINSONIN TAUTI; Parkinsonisme; Parkinson Syndrom/Morbus Parkinson; parkinson; parkinsonismus; Parkinsonismo; PARKINSONISME/PARALYSIS AGITANS; Parkinsonismo/paralisia agitante; Parkinsonismos; PARKINSOSNS SJUKDOM) =Disease or Syndrome ;
=basal ganglia disease; movement disorder; neurologic; Diagnosis/Diseases Component =paralysis agitans; Parkinson Disease, Secondary; DEMENTIA W LEWY BODIES |
- 525. PARATYPHOID FEVER A
- [ ] (UMLS (ICD9CM) C0343375) =Disease or Syndrome
| - 575. Parlodel
- (UMLS (NCI) C0000266) =Organic Chemical; Pharmacologic Substance ;
|
- 526. PARATYPHOID FEVER B
- (UMLS (ICD9CM) C0343376) =Disease or Syndrome
| - 576. Parnate
- (UMLS (NCI) C0701426) =Organic Chemical; Pharmacologic Substance ;
|
- 527. PARATYPHOID FEVER C
- (UMLS (ICD9CM) C0343377) =Disease or Syndrome
| - 577. parolfactory area
- [ ] (UMLS (CSP) C0228282) =Body Location or Region
|
- 528. Paraurethral Gland
- (UMLS (NCI) C0221315) =Body Part, Organ, or Organ Component ;
=Body Part;
| - 578. PAROMOMYCIN
- [An oligosaccharide antibiotic produced by various STREPTOMYCES. ( MSH )] (UMLS (NCI) C0030576) =Carbohydrate; Antibiotic =NEOMYCIN;
[AP900] ANTIPARASITICS, OTHER =Aminosidine Sulfate |
- 529. PARAURETHRAL SUSPENSION
- [ ] (UMLS (ICD9CM) C0194648) =Therapeutic or Preventive Procedure
| - 579. Paronal
- (UMLS (NCI) C1257721) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Enzyme
|
- 530. PARAVACCINIA NOS
- (UMLS (ICD9CM) C0026143) =Disease or Syndrome
| - 580. Paronychia
- [An inflammatory reaction involving the folds of the skin surrounding the fingernail. It is characterized by acute or chronic purulent, tender, and painful swellings of the tissues around the nail, caused by an abscess of the nail fold. The pathogenic yeast causing paronychia is most frequently Candida albicans. Saprophytic fungi may also be involved. The causative bacteria are usually Staphylococcus, Pseudomonas aeruginosa, or Streptococcus. (Andrews' Diseases of the Skin, 8th ed, p271) ( MSH )] (UMLS (HL7) C0030578) =Disease or Syndrome ;
=DISEASE OF NAIL NOS;
Skin Diseases, Infectious;
Body Part;
|
- 531. Paraxial Mesoderm
- [It lies next to the neural tube and will form SOMITES. ( MSH )] (UMLS (NCI) C1284009) =Embryonic Structure
| - 581. parosmia
- [ ] (UMLS (CSP) C1510410) =Sign or Symptom; ;
|
- 532. PARECOXIB
- (UMLS (NCI) C0915142) =Organic Chemical; Pharmacologic Substance ;
| - 582. Parotid
- [largest of the three pairs of salivary glands. ( CSP )] (UMLS (HL7) C0030580) =Body Part, Organ, or Organ Component ;
=Head and Neck, Salivary Glands;
Body Part |
- 533. Paredrine
- (UMLS (NCI) C0795751) =Organic Chemical; Pharmacologic Substance
| - 583. Parotid Duct
- (UMLS (NCI) C0227458) =Body Part, Organ, or Organ Component
|
- 534. Parent
- (UMLS (HL7) C1546512) =Idea or Concept =Association;
| - 584. Parotid Gland Carcinosarcoma
- (UMLS (NCI) C1335357) =Neoplastic Process ;
|
- 535. Parent
- (UMLS (HL7) C1548666) =Idea or Concept =Patient_s Relationship to Insured;
◊ (UMLS (HL7) C1549085) Idea or Concept Signatory_s Relationship to Subject; | - 585. Parotid Gland MALT lymphoma
- (UMLS (NCI) C1335364) Parotid Gland Mucosa-Associated Lymphoid Tissue Lymphoma =Neoplastic Process ;
|
- 536. Parent
- [The player of the role is one who begets, gives birth to, or nurtures and raises the scoping entity (child). ( HL7V3.0 )] (UMLS (HL7) C1609612) =Intellectual Product =Family Member;
=Father;
natural parent;
parent in-law;
step parent;
Mother;
| - 586. Parotid Gland Sebaceous Lymphadenoma
- (UMLS (NCI) C1335366) Sebaceous Lymphadenoma of the Parotid Gland =Neoplastic Process ;
|
- 537. Parent
- [persons functioning as natural, adoptive, or substitute mother or father. ( CSP )] (UMLS (NCI) C0030551) =Family Group ;
=Familial;
CoverageRoleType | - 587. Parotid Gland Squamous Cell Carcinoma
- (UMLS (NCI) C1335367) Parotid Squamous Cell Carcinoma;
Squamous Cell Carcinoma of Parotid;
Squamous Cell Carcinoma of Parotid Gland;
Squamous Cell Carcinoma of the Parotid;
Squamous Cell Carcinoma of the Parotid Gland =Neoplastic Process ;
|
- 538. parent child interaction
- [relationships and behaviors of father and mother with a child; including biological, adopted or step children. ( CSP )] (UMLS (CSP) C0030542) =Social Behavior =family dynamics;
=mother child interaction;
parent deprivation;
father child interaction | - 588. Parotidectomy
- [Surgery involving complete or partial excision of the parotid gland. ( NCI )] (UMLS (NCI) C0193317) =Therapeutic or Preventive Procedure
|
- 539. parent deprivation
- [prolonged separation of the offspring from the parents. ( CSP )] (UMLS (CSP) C0597176) =Human-caused Phenomenon or Process =parent child interaction;
=mother deprivation | - 589. PAROX ATRIAL TACHYCARDIA
- [An episodic form of supraventricular tachycardia, with abrupt onset and termination. ( NCI )] (UMLS (ICD9CM) C0030590) =Disease or Syndrome ;
|
- 540. parent in-law
- [The player of the role is the parent of scoping person's husband or wife. ( HL7V3.0 )] (UMLS (HL7) C1553707) =Intellectual Product =Parent;
=father-in-law;
mother-in-law | - 590. PAROX VENTRIC TACHYCARD
- [An episodic form of ventricular tachycardia, with abrupt onset and termination. ( NCI )] (UMLS (ICD9CM) C0030591) =Disease or Syndrome ;
|
- 541. Parent location
- (UMLS (HL7) C1548585) =Intellectual Product =Location Relationship ID;
| - 591. paroxetine
- [serotonin uptake inhibitor used in the treatment of depression. ( CSP )] (UMLS (CSP) C0070122) =Organic Chemical; Pharmacologic Substance =[CN600] ANTIDEPRESSANTS;
Piperidines;
serotonin inhibitor;
[CN609] ANTIDEPRESSANTS, OTHER =PAROXETINE HYDROCHLORIDE |
- 542. Parent Observation
- (UMLS (HL7) C1549569) =Idea or Concept =Derived specimen;
| - 592. Paroxetine Mesylate
- [The mesylate salt form of paroxetine, a phenylpiperidine derivative and a selective serotonin reuptake inhibitor (SSRI) with antidepressant and anxiolytic properties. Paroxetine binds to the pre-synaptic serotonin transporter complex resulting in negative allosteric modulation of the complex, thereby blocking reuptake of serotonin by the pre-synaptic transporter. Inhibition of serotonin recycling enhances serotonergic function through serotonin accumulation in the synaptic cleft, which resulting in long-term desensitization and downregulation of 5HT1 (serotonin) receptors and leading to symptomatic relief of depressive illness. ( NCI )] (UMLS (NCI) C1365510) PAROXETINE MESYLATE UNIDENTIFIED;
Paroxetine Methanesulfonate;
Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-,(3S,4R)-, Methanesulfonate;
=Organic Chemical; Pharmacologic Substance |
- 543. Parent order/service
- (UMLS (HL7) C1548248) =Intellectual Product =Order control codes;
| - 593. Paroxysmal Atrial Tachycardia
- [An episodic form of atrial tachycardia, with abrupt onset and termination. ( NCI )] (UMLS (NCI) C0030587) =Pathologic Function ;
|
- 544. Parent result link
- (UMLS (HL7) C1547385) =Idea or Concept =Data type;
| - 594. Paroxysmal Hypertension
- (UMLS (NCI) C0221154) =Sign or Symptom ;
|
- 545. Parent-child problems
- (UMLS (ICD9CM) C0700498) =Finding
| - 595. Paroxysmal tachycardia
- [Abnormally rapid heartbeats with sudden onset and cessation.(MSH)] (UMLS (ICPC) C0039236) (Paroxysmal tachycardia; EXTRASISTOLEAK,EDOZEIN TIPO; Paroksystisk takykardi; Paroxysmale tachycardie; KOHTAUKSITTAINEN SYDAMENTYKYTYS /PAROKSYSMAALINEN TAKYKARDIA; Tachycardie paroxystique; Paroxysmale Tachykardie; taxikardia paroksimalit; paroxysmalis tachycardia; Tachicardia parossistica; PAROKSYSMAL TAKYKARDI; Taquicardia paroxistica; Taquicardia paroxistica; PAROXYSMAL TAKYKARDI) =Disease or Syndrome =Heart Rate, Increased; CIRCULATORY; Diagnosis/Diseases Component;
|
- 546. parental age
- [ ] (UMLS (CSP) C0030543) =Group Attribute ;
| - 596. PARP
- [The human protein poly(ADP ribose) polymerase protein (1013aa, ~113 kDa) is encoded by the PARP1 gene (PARP1). Poly(ADP ribose) polymerase (PARP) is a cytosolic protein, and when activated is cleaved into two fragments of 89kd and 24kd. The enzyme modifies various nuclear proteins by poly(ADP-rybosyl)ation. The protein is involved in the regulation of various important cellular processes such as differentiation, proliferation, tumor transformation, and recovery from DNA damage. Its inhibition has been studied in cancerous cells and degenerative diseases to demonstrate how apoptosis can be inhibited when the PARP is inactive or absent. ( NCI )] (UMLS (NCI) C0032405) =Amino Acid, Peptide, or Protein; Enzyme
|
- 547. parenteral
- [Patient is supplied with parenteral nutrition, typically described in terms of i.v. medications. ( HL7V3.0 )] (UMLS (HL7) C1550568) =Therapeutic or Preventive Procedure =Diet;
| - 597. PARP Homolog
- [Tankyrase, a protein containing 24 ankyrin repeats and homology to the catalytic domain of PARP, is localized to human telomeres. The tankyrase ankyrin domain interacts with TRF1, which regulates telomere length by inhibiting telomerase. Tankyrase may have PARP activity and may function as acceptor for adenosine diphosphate (ADP)-ribosylation. Tankyrase may act as a positive regulator of telomere elongation by inhibiting TRF1; tankyrase-mediated ADP-ribosylation of TRF1 may open the telomeric complex, allowing access to telomerase. Tankyrase gene was mapped to 8p23.1. (from OMIM 603303 and NCI) ( NCI )] (UMLS (NCI) C0963182) Tankyrase;
Telomeric Poly (ADP-Ribose) Polymerase;
Telomeric Poly-(ADP-Ribose)-Polymerase;
TNKS;
TRF1-Interacting Ankyrin-Related ADP-Ribose Polymerase =Amino Acid, Peptide, or Protein; Enzyme ;
|
- 548. Parenteral & Enteral Nutrition
- (UMLS (HL7) C1552498) =Manufactured Object; Health Care Related Organization =Durable Medical Equipment & Medical Supplies;
| - 598. pars compacta
- [ ] (UMLS (CSP) C0175412) =Body Part, Organ, or Organ Component
|
- 549. Parenteral Dosage Form
- [A dosage form designed for administration not through the alimentary canal but rather by injection through some other route, such as subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, intrasternal, or intravenous. Formulations for parenteral administration include solutions, emulsions, suspensions, lyophilized formulations and sustained-release dosage forms. Common excipients used in parenteral formulations include: solvents and co-solvents; solubilizing, wetting, suspending, emulsifying or thickening agents; chelating agents; antioxidants and reducing agents; antimicrobial preservatives; buffers and pH adjusting agents and bulking agent, protectants and tonicity adjusters. ( NCI )] (UMLS (NCI) C1272936) Parenteral Dose Form;
=Pharmacologic Substance ;
| - 599. PARS inhibitor
- [ ] (UMLS (CSP) C0872240) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Enzyme
|
- 550. parenteral feeding
- [nutrients administered by a route other than the alimentary canal, for example intravenously or subcutaneously. ( CSP )] (UMLS (CSP) C1527385) =Therapeutic or Preventive Procedure ;
=diet route/schedule;
| - 600. pars intermedia
- [The intermediate lobe of the pituitary gland. It shows considerable size variation among the species, small in humans, and large in amphibians and lower vertebrates. This lobe produces mainly MELANOCYTE-STIMULATING HORMONES and other peptides from post-translational processing of pro-opiomelanocortin (POMC). ( MSH )] (UMLS (CSP) C0229531) =Body Part, Organ, or Organ Component
|
home
